Zacks‘ analyst wrote, “Pfizer posted first quarter earnings of $0.54 per share, a penny below the Zacks Consensus Estimate and 5% below the year-ago earnings. Results were hit by the loss of exclusivity of certain products and the unfavorable impact of currency fluctuation ($0.02 per share). Revenues, which fell 9% to $13.5 billion, missed the Zacks Consensus Estimate of $14.0 billion. Pfizer revised its outlook for 2013 to reflect the impact of the weak Japanese yen as well as the Zoetis IPO. Revenues will be hit by genericization and the expiration of a few co-promotion agreements. The company’s pipeline needs to deliver given the Lipitor loss of exclusivity and the upcoming loss of exclusivity on additional products in the next few years. We remain Neutral on the stock.”
A number of other analysts have also recently weighed in on PFE. Analysts at TheStreet reiterated a “buy” rating on shares of Pfizer in a research note to investors on Wednesday. Separately, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a research note to investors on Friday, April 26th. They now have a $32.00 price target on the stock. Finally, analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note to investors on Wednesday, April 17th. They now have a $33.00 price target on the stock, up previously from $31.00.
Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Pfizer has an average rating of “Buy” and an average target price of $31.00.
Pfizer (NYSE: PFE) traded up 0.17% on Wednesday, hitting $29.12. Pfizer has a 1-year low of $21.40 and a 1-year high of $31.15. The stock’s 50-day moving average is currently $29.07. The company has a market cap of $209.3 billion and a price-to-earnings ratio of 14.98.
Pfizer (NYSE: PFE) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by $0.01. The company had revenue of $13.50 billion for the quarter, compared to the consensus estimate of $14.10 billion. During the same quarter in the previous year, the company posted $0.58 earnings per share. The company’s revenue for the quarter was down 9.3% on a year-over-year basis. Pfizer has set its FY13 guidance at $2.14-2.24 EPS. On average, analysts predict that Pfizer will post $2.28 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, June 4th. Stockholders of record on Friday, May 10th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 3.30%. The ex-dividend date of this dividend is Wednesday, May 8th.
Pfizer Inc. (NYSE: PFE) is a research-based, global biopharmaceutical company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
